Hematopoietic stem cell transplantation (HSCT) represents a commonly employed and effective therapy for children affected by severe onco-hematological diseases. When a familial identical donor is not available, transplant with a matched unrelated donor (MUD) is the treatment of choice. 1 The major concern, in this setting, is the incidence and severity of GvHD, both acute (aGvHD) and chronic (cGvHD). For instance, previous data obtained in 54 MUD-transplanted children with SCID followed in our institution and in a Canadian pediatric referral center for primary immunodeficiency, demonstrated that 16% of patients developed aGvHD of grade III-IV, while 15% presented with cGvHD. 2 In MUDtransplanted patients, the mortality, which is 10%-40% at day +100, is highly correlated with aGvHD, type of disease, donor and stem cell source, conditioning and GvHD prophylaxis. 3, 4 As reported by Pai et al., 5 the use of T-cell depleted PBSC reduces GvHD in transplants with non HLA-identical donor, and several techniques have been used for T-cell depletion. Regulatory T cells have been also used to suppress GvHD without loss of graftversus-leukemia (GVL) activity. 6 In addition, the adoptive transfer and in vivo expansion of haploidentical TCR gamma/delta + T lymphocytes has a potential role in the treatment of hematological diseases by enhancing engraftment without inducing GvHD. 7 While there is no clear association between T-cell dose and incidence or severity of GvHD, it is known that the presence in the graft of a minimal T-cell dose is required to exert both graft versus tumor (GVT) and GvHD responses. 8 Indeed, in a consecutive series of 22 MUD transplants, we have previously found that the incidence of aGvHD of grade III-IV can be reduced to 9% if the number of infused donor T cells did not exceed 20-70 × 10 6 T cells/kg (Porta F, personal communication). Therefore, in order to improve engraftment and to avoid or decrease intensity and severity of aGvHD, in this pilot study we combined the last two approaches in three patients with infantile malignant osteopetrosis (IMO) candidate to MUD transplant. IMO is a rare genetic condition in which the increase of bone mass is caused by defects in osteoclast formation and function. A study, performed in our institution in 14 patients who received a total of 18 HSCT indicated that event-free survival (that included death, graft failure, loss of engraftment, severe infections, aGvHD of grade ⩾ III and cGvHD) was 80% after HSCT with matched sibling donors, 27.8% with MUD and 0% with mismatched related donor. 9 Furthermore, Driessen et al. 10 found that the 5-year disease-free survival in MUD-transplanted IMO patients was 40%, while an international survey performed in 125 patients demonstrated that it was 88% after transplants with matched sibling donor, 80% after MUD and 66% after haploidentical transplants.
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The major problem in children affected by IMO undergoing HSCT with MUD is late transplant failure 9 and, according to our own experience, only 50% of children achieved a sustained engraftment (Porta F, personal communication).
Of the three IMO patients transplanted with the procedure herein described, two have CLCN7 and one RANK gene defects (Table 1) , which are known to cause IMO with extremely heterogeneous phenotypes, sometimes milder than the classical phenotype. 11, 12 At the diagnosis and at the time of HSCT they showed typical clinical features of IMO, but not hematopoietic insufficiency, organomegaly, and did not require blood transfusions; only patient #1 showed visual problems and neurological impairment, including epilepsy and psychomotor retardation. The identification of HLA-matched donors (10/10 match for patients #1 and #2; HLA-DR3 and -DPB1 mismatches in patient #3) required about 2 months. Conditioning of the patients consisted, according to the European Group for Bone Marrow TransplantationEuropean Society for Immunodeficiencies guidelines (www.es id. org/downloads/OPGuide lines-2011), of busulfan (whose doses were adjusted on the basis of body weight and busulfan serum levels), fludarabine (40 mg/m 2 for 4 day), rabbit anti-thymocyte globulin (2.5 mg/kg/day; patients #1 and #2 from day − 5 to day − 2 and patient #3 from day − 5 to day − 3), and thiotepa (10 mg/kg in two doses).
The new strategy of HSCT we have used in the three patients consisted of the preparation of grafts containing a good number of CD34 + cells infused with TCR gamma/delta + cells, together with a preparation containing TCR alpha/beta + cells, that were initially depleted from the preparation and then repleted to a number not exceeding 25 × 10 6 cells/kg, and a limited number of CD19 + lymphocytes (Table 1) . In brief, a granulocyte-colony stimulating factor-stimulated leukapheresis was performed in MUD using a Cobe Spectra (Gambro BCT, Planegg-Martinsried, Germany). Mononuclear cells were incubated with CliniMACS TCR α/β-Biotin, CliniMACS anti-biotin and CliniMACS CD19 antibodies conjugated to paramagnetic particles; the mixture was processed with a fully automated device CliniMACS Plus (Miltenyi Biotec, Bergisch Gladbach, Germany) using the program "depletion 3.1" according to the manufacturer's instructions. The resulting products were analyzed by four-color FACS analysis using anti-TCR alpha/beta, -TCR gamma/delta, -CD3, -CD45, -CD56 and -CD20 monoclonal antibodies and 7-aminoactinomycin D. GvHD prophylaxis consisted of cyclosporine that is administered until 12 months after HSCT; mycophenolate mofetil was interrupted at day +30.
The mean numbers of infused CD34 + and TCR alpha/beta + cells were 18 × 10 6 /kg and 21.85 × 10 6 /kg, respectively, while infused TCR gamma/delta + cells were 127.5 × 10 6 /kg for patient #1, 62.7 × 10 6 /kg for patient #2 and 7.15 × 10 6 /kg for patient #3. WBC and platelet recovery was observed starting from day +13 ( Table 1) . Chimerism analysis, performed by means of DNA analysis of highly polymorphic loci demonstrated that a total donor engraftment was present in all patients until 6 months post transplant and it was still present at 10 and 11 months in patients #2 and #3. On the contrary, in patient #1, a decreased donor engraftment was observed starting at 7 months from HSCT and, at 12 months after HSCT, donor cells were 31, 11, 5 and 2% on CD3, CD19, CD15 and CD14 cell populations, respectively. The role of mixed chimerism on transplant outcome is still controversial, although it has been shown to correlate with an increased risk of graft failure. 13 However, owing to the good clinical conditions, this child is subjected only to a very strict follow-up. Furthermore, no correlation between late failure and number of infused T cells was observed in IMO transplanted patients.
Grade I GvHD was found only in patient #3 while, differently, we have previously found that five of nine patients with IMO who received MUD transplants developed GvHD, one of grade I, three of grade II and one of grade III. 9 Children did not show major infections. Following the clinical procedures performed in our institution, HSCT-IMO patients received Ig substitution for the entire period of observation and they did not undergo vaccinations yet, because this procedure is routinely performed after 1 year from HSCT, and by taking into account Ig levels ( Table 2) .
Post-HSCT immune recovery was assessed as previously described 14, 15 in several samples obtained until 10-12 months since HSCT. The immunophenotyping and the quantification of TCR excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) by duplex quantitative real-time PCR, which measure bone marrow and thymic output, respectively, revealed a progressive T-and B-cell immune recovery in patients #1, even at the time points at which donor cells were lost, as well as in patient #2 (Table 2 ). It is known that the increase of T cells containing TRECs early after HSCT appears to be the most reliable predictive marker for a long-lasting T-cell reconstitution. 16 Differently, thymic and bone marrow outputs were very low in patient #3, as indicated by the low or absent number of TRECs and naive CD4 + CD45RA + cells and of KRECs and CD19 + cells. At the end of the follow-up, the proliferative response to PHA was 97 000 cpm in patient #1, 182 000 cpm in patient #2, and only 3000 cpm in patient #3. Heteroduplex analysis, in which denatured and renatured amplified products of TCR beta variable genes chains migrate in polyacrylamide gels as smears in the case of a polyclonal repertoire, whereas heteroduplex or homoduplex bands indicate skewed conditions due to oligoclonal or clonal expansions, demonstrated an enlargement of TCR beta variable Abbreviations: ALC = absolute lymphocyte count; HSCT = hematopoietic stem cell transplantation; KRECs = kappa-deleting recombination excision circles; nd = not detectable; TRECs = TCR excision circles.
a Skewing of the TCR repertoire was scored when an oligoclonal pattern in two or more lanes was found in the heteroduplex gel: skewing in two to five lanes was defined as TCR score 1, skewing in more than five lanes was defined as TCR score 2. In nonskewed cases, polyclonal patterns or a single band were seen in all lanes, and these repertoires were defined as having TCR score 0.
repertoire complexity in patients #1 and #2. T-cell repertoire remained skewed all along the observation period in patient #3. The first two children are younger and have been transplanted sooner after the diagnosis than the other child, thus underlining the HSCT should be performed as soon as possible in patients with IMO related to RANK and CLCN7 mutations. 11 Owing to the poor immunological reconstitution, after 13 months since HSCT, patient #3 received a bone marrow boost (CD34 + cells 19.6 × 10 6 /kg; CD3 + cells 1 × 10 6 /kg) from the same donor. The proposed procedure not only may minimize or avoid GvHD but can also decrease the risk of EBV-associated lymphoproliferative syndromes since a limited number of CD19
+ cells was present in the graft, thus ensuring a prompt anti-infective activity. Furthermore, in two patients, the immune recovery seems to follow the feature observed in other HSCT performed for immunodeficiency. The use of a MUD transplant, which ensures the best probability of engraftment, 2,17 is of advantage for IMO patients if time is not lost until a full match instead of a haploidentical family donor is found. Indeed, a delay can be very crucial for the overall outcome, rejection and neurological complications.
Since T cells are mainly responsible for GvHD, manipulation of T cells remains the mainstay of GvHD prophylaxis. 18 Indeed, while it is known that a T-repleted MUD transplant has minor risks of rejection or graft failure, 19 the use of a haploidentical T-deplete transplant is the most effective means of prevention of GvHD. 18 The latter effect can be offset by increased risks of delayed immune reconstitution, leading to life-threatening infection, graft failure and disease recurrence. 20 Therefore, the transplantation of CD34 + cells together with TCR gamma/delta T cells, that may facilitate the engraftment, and with a controlled number of T lymphocytes that avoid graft failure and limit GvHD (in our cases we don't have severe GvHD) is a valid alternative of graft manipulation. Since we have tested this new method in three patients affected by IMO, a disease in which the graft is rather difficult, the encouraging results of this preliminary single center experience, even if obtained in a timesensitive patient population, suggest that this safe, effective and practical option can be worth to be performed in other clinical settings.
